Original articleIntraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Section snippets
Patient Selection and Sampling
We investigated 30 eyes of 30 patients (mean age, 71.1 years; age range, 43 to 93 years; 12 females, 18 males) treated at the Department of Ophthalmology, University of Bonn. Patients agreed to participate in the study by written informed consent.
We included patients who were scheduled for cataract surgery for clinically significant lens opacification and who in addition had previously received intravitreal bevacizumab therapy for macular edema in the same eye. The macular edema was secondary
Results
Bevacizumab concentrations were measured in aqueous humor samples obtained from 30 eyes of 30 patients after intravitreal injection of 1.5 mg in the same eye (Figure 2). Bevacizumab concentration peaked on postinjection day 1, with a mean concentration (cmax) of 33.3 μg/ml (n = 5; range, 16.6 to 42.5 μg/ml). Best fit for the decline of bevacizumab concentration over time was a first-order exponential decay function. Nonlinear regression analysis of the data was performed and reached a
Discussion
To date, only a limited number of reports on the pharmacokinetics of bevacizumab in animal or human eyes has been published. This study provides, to the best of our knowledge, the first investigation on the pharmacokinetics of intraocular bevacizumab in a human case series. In our study encompassing 30 patients, the half-life of bevacizumab in aqueous humor after intravitreal delivery of 1.5 mg was 9.82 days. Our findings are in accordance with a yet unpublished study by Csaky and associates,
References (21)
- et al.
Tunneled scleral incision to prevent vitreal reflux after intravitreal injection
Am J Ophthalmol
(2007) - et al.
Pharmacokinetics of intravitreal bevacizumab (Avastin)
Ophthalmology
(2007) - et al.
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
Ophthalmology
(2003) - et al.
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
Ophthalmology
(2007) - et al.
Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes
Am J Ophthalmol
(2007) - et al.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
N Engl J Med
(2004) - et al.
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study
Ophthalmology
(2005) - et al.
Intravitreal bevacizumab for neovascular age-related macular degeneration
Ophthalmologe
(2006) - et al.
Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema
Retina
(2006) - et al.
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
Ophthalmology
(2007)
Cited by (302)
Quantitative intravitreal pharmacokinetics in mouse as a step towards inter-species translation
2023, Experimental Eye ResearchOcular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies
2023, Advanced Drug Delivery ReviewsAnalysis of the sustained release ability of bevacizumab-loaded tetra-PEG gel
2022, Experimental Eye ResearchCitation Excerpt :However, the patients require frequent injections due to the rapid clearance of the drug from the vitreous. Krohne et al. investigated the half-life of bevacizumab (Krohne et al., 2008) and ranibizumab (Krohne et al., 2012) in the aqueous humor of the human eye and reported that the half-lives were 9.82 and 7.19 days for bevacizumab and ranibizumab, respectively. Beer et al. reported that the intravitreal half-life of bevacizumab was approximately three days in humans (Beer et al., 2006).
Ocular pharmacokinetics
2022, Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics